Key Players
- Gilead Sciences
- Janssen Therapeutics
- Division of Janssen Products
- AbbVie
- Bristol-Myers Squibb
- Merck & AND companies IS NULL; Co.
- Vertex Pharmaceuticals
- such as AbbVie is developing ABT-530 (an NS5A inhibitor)
- ABT-493 (a protease inhibitor)
- Gilead's FDC of sofosbuvir
